Fig. 2

TRF2 enhances TNBC cell sensitivity to taxanes. a-c Cell survival evaluation by clonogenic assay in human triple negative breast cancer (TNBC) cell lines, MDA-MB-231, over-expressing (pTRF2) or not (pBabe) TRF2 and treated with three taxanes (Paclitaxel a, Docetaxel b and Cabazitaxel c) at the indicated doses for 24 hours. d Representative images of the clonogenic assays described in a-c. e Clonogenic assay performed in TNBC cell lines MDA-MB-231 pBabe or pTRF2 pretreated with Chloroquine (CQ) 10 mM for 24 hours before the administration of Paclitaxel 1 nM for 24 hours. The graphs represent the mean values ± S.D. of at least three independent experiments. *p<0.05, **p<0.01, ***p <0.001, ****p<0.0001.